Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the...
First of its Kind in Biotherapeutic Antibody Characterization TORRANCE, Calif., March 25, 2025 /PRNewswire/ -- Phenomenex Inc., a global leader in...
AD/PD™ 2025 to feature presentations on Linus Health's digital cognitive health assessments, plus attendees can learn more about company's recent...
NEW YORK, March 25, 2025 /PRNewswire/ -- DeepIntent, the leading healthcare advertising technology company, today introduced DeepIntent Cortex, its most...
LiveWorld looks to increase its AI investmentCAMPBELL, Calif. and NEW YORK , March 25, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc....
Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March...
Helicore’s first-in-human study is designed to evaluate the safety and tolerability of HCR-188 in a single and multiple ascending dose...
RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone...
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today...
Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors;...
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company developing...
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected...
FREDERICK, Md., March 25, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a leader in disinfection and...
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two...
- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support...
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with...
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to...
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform...
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential...